Shares of the Renovo Group Plc plunged by 75% on the London Stock Exchange on 11 February 2011 after the company announced that its first Phase 3 trial for Juvista (avotermin) for use in scare revision surgery failed to meet all clinical endpoints. ---Subscribe to MedNous to access this article--- Company News
